Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $1.6 million.

  • Ironwood Pharmaceuticals' Accounts Payables fell 5015.45% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 5015.45%. This contributed to the annual value of $2.1 million for FY2024, which is 7283.52% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Accounts Payables of $1.6 million as of Q3 2025, which was down 5015.45% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Accounts Payables ranged from a high of $7.8 million in Q4 2023 and a low of $118000.0 during Q1 2023
  • Moreover, its 5-year median value for Accounts Payables was $1.4 million (2025), whereas its average is $2.3 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Accounts Payables plummeted by 7900.61% in 2021, and later skyrocketed by 517288.14% in 2024.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Accounts Payables stood at $935000.0 in 2021, then tumbled by 48.34% to $483000.0 in 2022, then surged by 1521.12% to $7.8 million in 2023, then plummeted by 72.84% to $2.1 million in 2024, then decreased by 24.17% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.4 million for Q2 2025, and $5.8 million during Q1 2025.